• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock

    Simply Wall St·07/21/2026 00:33:54
    Listen to the news

    IRADIMED stock snapshot after recent performance

    IRADIMED (IRMD) has drawn fresh attention after a period of steady trading, with the stock flat over the past day while showing gains over the past month and past 3 months.

    See our latest analysis for IRADIMED.

    At a share price of $97.03, IRADIMED has seen a 30 day share price return of 5.24% and a 1 year total shareholder return of 75.09%. This suggests recent momentum has built on already strong longer term gains.

    If IRADIMED's move has caught your eye and you want to see what else the market might be pricing for growth in medical technology, take a look at 39 healthcare AI stocks.

    IRADIMED’s strong 1 year return and recent 30 day gain can hint at growing conviction in its MRI compatible equipment business, or simply a swing in sentiment around the stock. So how does the current valuation stack up?

    Most Popular Narrative: 18% Undervalued

    Analysts following IRADIMED see a fair value of $118 per share, which sits above the current $97.03 price and underpins the latest bullish narrative.

    The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large-scale, recurring device and consumable revenues. This supports a step-change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.

    Read the complete narrative.

    Want to see what is built into that $118 fair value for IRADIMED? The narrative leans on steady revenue expansion, firm margins and a richer future earnings multiple. The specific mix of growth and pricing assumptions is where the story gets interesting.

    Based on this widely followed narrative and a 7.44% discount rate, IRADIMED’s share price is treated as trading below estimated fair value, with the gap tied to expectations for MRI compatible equipment demand, profitability and future valuation multiples. Result: Fair Value of $118 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the IRADIMED story can change quickly if hospitals pull back on MRI equipment spending or if supply chain issues extend already lengthy delivery timelines.

    Find out about the key risks to this IRADIMED narrative.

    Another View: IRADIMED looks pricey on earnings multiples

    The analyst narrative describes IRADIMED as undervalued relative to a $118 fair value, but the current P/E of 52.5x presents a more demanding picture. This is well above the US Medical Equipment industry at 27.2x, the peer average at 44.6x, and a reference ratio of 20.1x. For investors, that gap can mean paying a higher price today for expectations that already appear elevated. The key question is how comfortable you are with what is currently reflected in the share price.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGM:IRMD P/E Ratio as at Jul 2026
    NasdaqGM:IRMD P/E Ratio as at Jul 2026

    Next Steps

    If this mixed sentiment around IRADIMED leaves you uncertain, take a moment to review the full picture and weigh both sides through 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond IRADIMED?

    IRADIMED may be on your radar today, but widening your watchlist with a few focused stock ideas can help you spot opportunities you might otherwise miss.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.